Literature DB >> 4122562

Active immunotherapy with B.C.G. for recurrent malignant melanoma.

J U Gutterman, G Mavligit, C McBride, E Frei, E J Freireich, E M Hersh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4122562     DOI: 10.1016/s0140-6736(73)90526-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  31 in total

Review 1.  Cell walls of Mycobacteria and related organisms; chemistry and immunostimulant properties.

Authors:  E Lederer; A Adam; R Ciorbaru; J F Petit; J Wietzerbin
Journal:  Mol Cell Biochem       Date:  1975-05-30       Impact factor: 3.396

2.  New experimental and clinical data on leukaemia immunotherapy.

Authors:  G Mathé; L Schwarzenberg; J L Amiel; P Pouillart; M Hayat; F de Vassal; C Rosenfeld; C Jasmin
Journal:  Proc R Soc Med       Date:  1975-04

3.  Long-term survival after removal of primary intracranial malignant melanoma. Case report.

Authors:  H Nakagawa; T Hayakawa; K Niiyama; Y Nii; T Yoshimine; S Mori
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

5.  The effect of BCG-vaccination on vaccinia virus infections in mice.

Authors:  G T Werner
Journal:  Experientia       Date:  1979-11-15

Review 6.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 7.  [The immunology of malignant melanoma (author's transl)].

Authors:  G Schieferstein
Journal:  Klin Wochenschr       Date:  1978-03-15

8.  Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial).

Authors:  H M Jansen; T H The; G C de Gast; M T Esselink; A M van der Wal; N G Orie
Journal:  Thorax       Date:  1978-08       Impact factor: 9.139

9.  The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.

Authors:  N Cascinelli; P Rümke; R MacKie; A Morabito; R Bufalino
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Adjuvant BCG immunotherapy for malignant melanoma.

Authors:  A H Paterson; D J Willans; L M Jerry; J Hanson; T A McPherson
Journal:  Can Med Assoc J       Date:  1984-10-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.